HK1155647A1 - Solid oral composition comprising a s1p receptor agonist and a sugar alcohol s1p - Google Patents

Solid oral composition comprising a s1p receptor agonist and a sugar alcohol s1p

Info

Publication number
HK1155647A1
HK1155647A1 HK11109933.8A HK11109933A HK1155647A1 HK 1155647 A1 HK1155647 A1 HK 1155647A1 HK 11109933 A HK11109933 A HK 11109933A HK 1155647 A1 HK1155647 A1 HK 1155647A1
Authority
HK
Hong Kong
Prior art keywords
receptor agonist
sugar alcohol
oral composition
solid oral
solid
Prior art date
Application number
HK11109933.8A
Other languages
English (en)
Chinese (zh)
Inventor
Tomoyuki Oomura
Madhusudhan Pudipeddi
Alan Edward Royce
Colleen Ruegger
Masaki Sasaki
Tokuhiro Tamura
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1155647(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1155647A1 publication Critical patent/HK1155647A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
HK11109933.8A 2003-04-08 2011-09-21 Solid oral composition comprising a s1p receptor agonist and a sugar alcohol s1p HK1155647A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08

Publications (1)

Publication Number Publication Date
HK1155647A1 true HK1155647A1 (en) 2012-05-25

Family

ID=32326722

Family Applications (3)

Application Number Title Priority Date Filing Date
HK05102715A HK1071685A1 (en) 2003-04-08 2005-03-31 Pharmaceutical composition comprising an s1p receptor agonist
HK06107621.6A HK1091114A1 (en) 2003-04-08 2006-07-06 Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
HK11109933.8A HK1155647A1 (en) 2003-04-08 2011-09-21 Solid oral composition comprising a s1p receptor agonist and a sugar alcohol s1p

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK05102715A HK1071685A1 (en) 2003-04-08 2005-03-31 Pharmaceutical composition comprising an s1p receptor agonist
HK06107621.6A HK1091114A1 (en) 2003-04-08 2006-07-06 Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol

Country Status (42)

Country Link
US (11) US20060275357A1 (xx)
EP (5) EP2769713A1 (xx)
JP (3) JP5495467B2 (xx)
KR (3) KR20110005320A (xx)
CN (2) CN101797241B (xx)
AR (3) AR043987A1 (xx)
AT (3) ATE414508T1 (xx)
AU (1) AU2004228929B2 (xx)
BE (2) BE1015972A5 (xx)
BR (1) BRPI0409250B8 (xx)
CA (2) CA2521325C (xx)
CL (2) CL2004000745A1 (xx)
CY (3) CY1110260T1 (xx)
DE (4) DE602004017847D1 (xx)
DK (2) DK1613288T3 (xx)
EC (1) ECSP056090A (xx)
ES (3) ES2228282B1 (xx)
FR (2) FR2854073B1 (xx)
GB (1) GB2400318B (xx)
GR (1) GR1005052B (xx)
HK (3) HK1071685A1 (xx)
HR (3) HRP20050886B1 (xx)
HU (2) HUE028247T2 (xx)
IL (3) IL170888A (xx)
IS (2) IS2682B (xx)
IT (1) ITMI20040682A1 (xx)
LU (1) LU91867I2 (xx)
MA (1) MA27729A1 (xx)
MX (1) MXPA05010860A (xx)
MY (1) MY141249A (xx)
NO (4) NO329332B1 (xx)
NZ (3) NZ592339A (xx)
PE (5) PE20090743A1 (xx)
PL (2) PL1613288T3 (xx)
PT (1) PT1613288E (xx)
RU (5) RU2358716C2 (xx)
SG (1) SG175449A1 (xx)
SI (2) SI2316431T1 (xx)
TN (1) TNSN05256A1 (xx)
TW (1) TWI332847B (xx)
WO (1) WO2004089341A1 (xx)
ZA (1) ZA200507394B (xx)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1773307E (pt) * 2004-07-30 2015-01-14 Novartis Ag Formulações de compostos à base de 2-amino-1,3- propanodiol
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
SG165364A1 (en) * 2005-09-09 2010-10-28 Novartis Ag Treatment of autoimmune diseases
US8716322B2 (en) 2005-11-09 2014-05-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
NZ573759A (en) 2006-06-19 2012-03-30 Proteolix Inc Peptide epoxyketones for proteasome inhibition
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
AU2007302296A1 (en) * 2006-09-26 2008-04-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
SI2140867T2 (sl) 2007-03-29 2023-10-30 Daiichi Sankyo Company, Limited Farmacevtski sestavek
MY166950A (en) 2007-10-04 2018-07-25 Onyx Therapeutics Inc Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
CN101820916A (zh) 2007-10-12 2010-09-01 诺瓦提斯公司 包含鞘氨醇1磷酸(s1p)受体调节剂的组合物
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
JP5452237B2 (ja) 2008-02-07 2014-03-26 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
JP4846063B2 (ja) 2008-03-17 2011-12-28 アクテリオン ファーマシューティカルズ リミテッド 選択的ｓ１ｐ１レセプターアゴニストの投与法
CN104800196A (zh) 2008-06-20 2015-07-29 诺华股份有限公司 用于治疗多发性硬化的儿科组合物
RU2519768C2 (ru) * 2008-06-20 2014-06-20 Мерк Патент Гмбх Поддающаяся прямому прессованию и быстро распадающаяся матрица таблетки
CA2735037C (en) * 2008-09-04 2016-07-12 Cargill Incorporated Tabletting of erythritol
EP2349313A4 (en) 2008-10-21 2012-08-29 Onyx Therapeutics Inc COMBINATION THERAPY WITH EPOXYCLETON PEPTIDES
JP2012508216A (ja) * 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
AU2013100533B4 (en) * 2008-11-11 2013-12-12 Novartis Ag Crystalline forms of fingolimod HCL
JP2012508215A (ja) 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
KR101463653B1 (ko) 2008-12-17 2014-11-19 다이이찌 산쿄 가부시키가이샤 디아민 유도체의 제조 방법
WO2010082531A1 (ja) 2009-01-13 2010-07-22 第一三共株式会社 活性化血液凝固因子阻害剤
JP5666424B2 (ja) 2009-03-10 2015-02-12 第一三共株式会社 ジアミン誘導体の製造方法
CN102348680B (zh) 2009-03-13 2014-11-05 第一三共株式会社 用于制备光学活性二胺衍生物的方法
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
CN102481296A (zh) * 2009-06-18 2012-05-30 第一三共株式会社 溶解性改善的药用组合物
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
CN102892417A (zh) 2010-03-01 2013-01-23 欧尼斯治疗公司 用于免疫蛋白酶体抑制的化合物
WO2011115066A1 (ja) 2010-03-19 2011-09-22 第一三共株式会社 ジアミン誘導体の結晶およびその製造方法
KR101792299B1 (ko) 2010-03-19 2017-10-31 다이이찌 산쿄 가부시키가이샤 항응고제의 용출 개선 방법
CA2797029A1 (en) * 2010-04-22 2011-10-27 Ratiopharm Gmbh A method of preparing an oral dosage form comprising fingolimod
CA2804262C (en) 2010-07-02 2016-04-05 Daiichi Sankyo Company, Limited Process for preparation of optically active diamine derivative salt
EP2646409A4 (en) 2010-11-25 2015-12-16 Shilpa Medicare Ltd FINGOLIMODE POLYMORPHS AND METHODS THEREOF
DK2665471T3 (en) 2011-01-19 2018-03-19 Pathologica Llc ORAL PHARMACEUTICAL DOSAGE FORMS WITH MANAGED RELEASE COMPREHENSIVE MGBG
AR085749A1 (es) * 2011-04-01 2013-10-23 Novartis Ag Formulaciones
US9186333B2 (en) * 2011-08-01 2015-11-17 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions of fingolimod
CN103732227B (zh) 2011-08-10 2017-04-12 第一三共株式会社 含有二胺衍生物的药物组合物
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
TW201414751A (zh) 2012-07-09 2014-04-16 歐尼克斯治療公司 肽環氧酮蛋白酶抑制劑之前驅藥物
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
US10085955B2 (en) * 2013-01-08 2018-10-02 Pathologica Llc Methods and compositions for treatment of demyelinating diseases
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
EP2990055B1 (en) * 2013-04-26 2019-06-05 Kyoto University Composition comprising a sphingosine-1-phosphate receptor 1 agonist for inhibiting formation and/or enlargement of cerebral aneurysm or for shrinking it
ES2770500T3 (es) * 2013-05-13 2020-07-01 Synthon Bv Composición farmacéutica que comprende fingolimod
JP6316422B2 (ja) * 2013-07-29 2018-04-25 アイザント ドラッグ リサーチ ソリューションズ プライベート リミテッドＡｉｚａｎｔ Ｄｒｕｇ Ｒｅｓｅａｒｃｈ Ｓｏｌｕｔｉｏｎｓ Ｐｖｔ Ｌｔｄ フィンゴリモドの医薬組成物
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
CN106794159A (zh) * 2014-08-22 2017-05-31 广东东阳光药业有限公司 一种芬戈莫德固体组合物及其制备方法
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
CA2974375A1 (en) * 2015-01-20 2016-07-28 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
WO2018178744A1 (en) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) * 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
WO2022015348A1 (en) 2020-07-16 2022-01-20 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
DE122011100012I1 (de) 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
DK0778263T3 (da) 1994-08-22 2002-04-22 Mitsubishi Pharma Corp Benzenforbindelser og farmaceutisk anvendelse af disse
EP0812588B1 (en) 1995-12-28 2004-10-13 Mitsubishi Pharma Corporation Pharmaceutical external preparations for topical administration comprising 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol for the treatment of diseases induced from immune disorder
JP2002241272A (ja) 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
DK0990440T3 (da) * 1997-02-27 2009-02-23 Novartis Ag Farmaceutisk sammensætning indeholdende 2-amino-2[2-(4-octylphenyl)-ethyl]-propan-1,3-diol, en lecithin og et saccharid
IL155066A (en) 1997-04-04 2004-06-20 Mitsubishi Pharma Corp History 2 - Amino - 2 - (2 - Ethyl (converted)) Propane - 1, 3 - Diol Efficacy in the preparation of 2 - Aminopropene - 1, 3 - Diol
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
KR20020027463A (ko) * 1999-07-12 2002-04-13 우에노 도시오 스핀고신-1-인산 수용체 아고니스트 또는스핀고신-1-인산을 유효 성분으로서 함유하는 선유화 억제제
NZ523554A (en) 2000-07-13 2004-12-24 Sankyo Co Amino alcohol derivatives
CA2421893A1 (en) * 2000-08-31 2002-03-07 Merck And Co., Inc. Phosphate derivatives as immunoregulatory agents
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
SK11942003A3 (sk) 2001-03-26 2004-03-02 Novartis Ag Deriváty 2-aminopropanolu, ich použitie a farmaceutická kompozícia, ktorá ich obsahuje
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
EP1424078A4 (en) 2001-09-04 2009-03-25 Ono Pharmaceutical Co RESPIRATORY DISEASE MEDICINES COMPRISING A SPHINGOSINE-1-PHOSPHATE RECEPTOR REGULATING AGENT
EP1431284B1 (en) 2001-09-27 2007-11-21 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
ATE463478T1 (de) 2001-09-27 2010-04-15 Kyorin Seiyaku Kk Diaryletherderivat, dessen additionssalz und immunosuppressivum
US20050070506A1 (en) 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
US7351725B2 (en) 2002-01-18 2008-04-01 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
JP2005519915A (ja) 2002-01-18 2005-07-07 セレテック・リミテッド・ライアビリティ・カンパニー Ｅｄｇ受容体に関連する症状の処置方法
JP4430941B2 (ja) 2002-01-18 2010-03-10 メルク エンド カムパニー インコーポレーテッド Ｅｄｇ受容体作動薬
DE602005027074D1 (de) * 2004-07-16 2011-05-05 Kyorin Seiyaku Kk Verfahren zur effektiven anwendung eines medikaments und verfahren zur prävention von nebenwirkungen

Also Published As

Publication number Publication date
LU91867I2 (fr) 2011-11-08
DE122011100047I1 (de) 2011-12-15
SI1613288T1 (sl) 2009-04-30
BRPI0409250B8 (pt) 2022-01-18
CA2521325C (en) 2010-09-14
RU2358716C2 (ru) 2009-06-20
US20140011885A1 (en) 2014-01-09
ATE414508T1 (de) 2008-12-15
EP2008650A2 (en) 2008-12-31
US20080311188A1 (en) 2008-12-18
DK2316431T3 (en) 2016-01-11
HRP20100601A2 (hr) 2011-03-31
US20200237690A1 (en) 2020-07-30
DE202004021680U1 (de) 2010-04-22
RU2010147000A (ru) 2012-08-10
IS8114A (is) 2005-11-01
NO20055231D0 (no) 2005-11-07
EP2769713A1 (en) 2014-08-27
DK1613288T3 (da) 2009-03-23
WO2004089341A1 (en) 2004-10-21
PE20150676A1 (es) 2015-05-17
PE20050396A1 (es) 2005-07-05
GR1005052B (el) 2005-11-30
AR078781A2 (es) 2011-11-30
HRP20050886A2 (en) 2006-11-30
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
US8324283B2 (en) 2012-12-04
NO335120B1 (no) 2014-09-22
US20060275357A1 (en) 2006-12-07
CN101797241A (zh) 2010-08-11
RU2475237C2 (ru) 2013-02-20
KR20050121712A (ko) 2005-12-27
RU2012148593A (ru) 2014-05-20
CY1110260T1 (el) 2014-04-09
NO334116B1 (no) 2013-12-16
HRP20100601B1 (hr) 2016-12-02
IL170888A (en) 2010-06-16
FR11C0036I2 (fr) 2023-12-29
RU2009105403A (ru) 2010-08-27
RU2005134173A (ru) 2006-09-10
FR11C0036I1 (fr) 2011-10-14
TWI332847B (en) 2010-11-11
EP1613288B1 (en) 2008-11-19
DE602004017847D1 (de) 2009-01-02
NO329332B1 (no) 2010-09-27
IE20040246A1 (en) 2004-12-15
MA27729A1 (fr) 2006-01-02
CY2011013I2 (el) 2014-04-09
JP5495467B2 (ja) 2014-05-21
US20110105620A1 (en) 2011-05-05
AT501681A1 (de) 2006-10-15
RU2010146697A (ru) 2012-05-27
AR078782A2 (es) 2011-11-30
ECSP056090A (es) 2006-03-01
ITMI20040682A1 (it) 2004-07-06
IS2682B (is) 2010-10-15
HRP20100600A2 (hr) 2011-03-31
MXPA05010860A (es) 2006-05-25
GB2400318A (en) 2004-10-13
US20190175527A1 (en) 2019-06-13
SI2316431T1 (sl) 2016-04-29
CY1117071T1 (el) 2017-04-05
HUS1100016I1 (hu) 2016-08-29
BRPI0409250B1 (pt) 2017-07-11
JP2004307506A (ja) 2004-11-04
EP2319502A1 (en) 2011-05-11
KR101367574B1 (ko) 2014-02-25
PE20090743A1 (es) 2009-07-17
EP2316431B1 (en) 2015-09-30
EP1613288A1 (en) 2006-01-11
NO2011016I2 (no) 2012-08-27
MY141249A (en) 2010-03-31
PE20131352A1 (es) 2013-11-14
GB0407819D0 (en) 2004-05-12
ZA200507394B (en) 2007-03-28
DE102004016947A1 (de) 2004-10-21
ES2320767T3 (es) 2009-05-28
PT1613288E (pt) 2009-02-25
AT501681B1 (de) 2012-04-15
JP2013177404A (ja) 2013-09-09
NZ586280A (en) 2011-12-22
CY2011013I1 (el) 2014-04-09
IS8885A (is) 2010-02-25
ES2228282A1 (es) 2005-04-01
FR2854073B1 (fr) 2008-03-14
HK1091114A1 (en) 2007-01-12
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
KR20120101148A (ko) 2012-09-12
AU2004228929B2 (en) 2008-02-07
PL1613288T3 (pl) 2009-07-31
CA2521325A1 (en) 2004-10-21
PE20130200A1 (es) 2013-03-09
US20130108675A1 (en) 2013-05-02
LU91867I9 (xx) 2019-01-03
IL197578A (en) 2015-10-29
US20090203798A1 (en) 2009-08-13
AU2004228929A1 (en) 2004-10-21
NZ542622A (en) 2009-01-31
HRP20050886B1 (en) 2011-01-31
CN101797241B (zh) 2013-03-27
EP2316431A1 (en) 2011-05-04
HK1071685A1 (en) 2005-07-29
GB2400318B (en) 2005-08-10
CL2004000745A1 (es) 2005-02-11
IL197578A0 (en) 2011-07-31
BE2011C030I2 (xx) 2023-03-07
TNSN05256A1 (en) 2007-07-10
JP2011006461A (ja) 2011-01-13
GR20040100121A (el) 2004-12-17
ES2228282B1 (es) 2006-02-16
CN1767819A (zh) 2006-05-03
ES2556947T3 (es) 2016-01-21
HUE028247T2 (en) 2016-12-28
CA2707750A1 (en) 2004-10-21
US20220031609A1 (en) 2022-02-03
AT504853A2 (de) 2008-08-15
JP5543298B2 (ja) 2014-07-09
IL242037A0 (en) 2015-11-30
EP2008650A3 (en) 2011-04-27
KR20110005320A (ko) 2011-01-17
BRPI0409250A (pt) 2006-03-28
SG175449A1 (en) 2011-11-28
RU2475236C2 (ru) 2013-02-20
TW200503784A (en) 2005-02-01
NO20100250L (no) 2006-01-09
US20170290787A1 (en) 2017-10-12
AR043987A1 (es) 2005-08-17
NZ592339A (en) 2012-09-28
NO2011016I1 (no) 2011-09-19
NO20131287L (no) 2006-01-09
FR2854073A1 (fr) 2004-10-29
CN1767819B (zh) 2010-07-28
US20140255497A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
HK1155647A1 (en) Solid oral composition comprising a s1p receptor agonist and a sugar alcohol s1p
PT2277521E (pt) Formulações orais de agonistas de opióides resistentes a adulteração
HK1085131A1 (en) Solid drug for oral use
ZA200508733B (en) Muscarinic M1 receptor agonists for pain management
EP1701691A4 (en) METHODS AND COMPOSITIONS FOR ORAL HYGIENE
ZA200606174B (en) Multiparticulate formulations for oral delivery
EP1757273A4 (en) PREPARATION FOR ORAL ADMINISTRATION
PL1797871T3 (pl) Długo działający preparat o przedłużonym uwalnianiu zawierający agonistę receptora dopaminowego i sposób jego wytwarzania
IL177826A0 (en) Oral matrix formulations comprising licarbazepine
GB2391809B (en) Pharmaceutical composition comprising honey
EP1811967A4 (en) METHOD AND FORMULATIONS FOR PREPARING PHARMACEUTICAL COMPOSITIONS WITH BUPROPION
IL161997A (en) Pharmaceutical composition comprising a 5ht1 receptor agonist
EP1755477A4 (en) MOUTH HYGIENE COMPOSITIONS AND METHOD OF USE THEREOF
AU2003252683A8 (en) Composition for oral use
IL178296A0 (en) Pharmaceutical compositions containing a gaba?? receptor agonist
GB0325383D0 (en) Oral formulations
GB2403407B (en) Palatable oral anthelmintic composition
EP1614417A4 (en) SOLID PREPARATION FOR ORAL USE
PL377147A1 (pl) Doustna kompozycja
AU2003280065A1 (en) Bupropion hydrochloride solid dosage forms
GB0406393D0 (en) Oral composition
GB0406392D0 (en) Oral composition
GB0413138D0 (en) Preparation for oral administration
AU2004900654A0 (en) Oral Hygiene Device

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190409